Antiviral Effect, Safety, and Tolerability of Oral VH4011499 (VH-499), a New HIV-1 Capsid Inhibitor: Proof-of-Concept Trial.

Griesel R, Nuñez SA, Cordova E, Pérez Rios AM, Ridilenir VL, Lehmann C, Slim J, Arenzana CB, Szabo J, Cahn P, Post FA, Pierce A, Pestrak M, Jeffrey JL, Thakkar N, Shepherd B, Bainbridge V, Angelis K, McMillan C, Benn P

Open source

DOI: 10.1093/cid/ciag452
Published: 2026 Jul 29
Container: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/cid/ciag452,
  title = {Antiviral Effect, Safety, and Tolerability of Oral VH4011499 (VH-499), a New HIV-1 Capsid Inhibitor: Proof-of-Concept Trial.},
  author = {Griesel R and Nuñez SA and Cordova E and Pérez Rios AM and Ridilenir VL and Lehmann C and Slim J and Arenzana CB and Szabo J and Cahn P and Post FA and Pierce A and Pestrak M and Jeffrey JL and Thakkar N and Shepherd B and Bainbridge V and Angelis K and McMillan C and Benn P},
  year = {2026},
  journal = {Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
  doi = {10.1093/cid/ciag452},
  url = {https://doi.org/10.1093/cid/ciag452}
}

RIS

TY  - JOUR
TI  - Antiviral Effect, Safety, and Tolerability of Oral VH4011499 (VH-499), a New HIV-1 Capsid Inhibitor: Proof-of-Concept Trial.
AU  - Griesel R
AU  - Nuñez SA
AU  - Cordova E
AU  - Pérez Rios AM
AU  - Ridilenir VL
AU  - Lehmann C
AU  - Slim J
AU  - Arenzana CB
AU  - Szabo J
AU  - Cahn P
AU  - Post FA
AU  - Pierce A
AU  - Pestrak M
AU  - Jeffrey JL
AU  - Thakkar N
AU  - Shepherd B
AU  - Bainbridge V
AU  - Angelis K
AU  - McMillan C
AU  - Benn P
PY  - 2026
JO  - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
DO  - 10.1093/cid/ciag452
UR  - https://doi.org/10.1093/cid/ciag452
ER  -

APA

R, G., SA, N., E, C., AM, P. R., VL, R., C, L., J, S., CB, A., J, S., P, C., FA, P., A, P., M, P., JL, J., N, T., B, S., V, B., K, A., C, M., & P, B. (2026). Antiviral Effect, Safety, and Tolerability of Oral VH4011499 (VH-499), a New HIV-1 Capsid Inhibitor: Proof-of-Concept Trial.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. https://doi.org/10.1093/cid/ciag452

Source records

pubmed · retrieved 2026-09-25T23:03:45.400Z
europe-pmc · retrieved 2026-09-25T23:03:45.419Z